SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-021239
Filing Date
2023-05-11
Accepted
2023-05-11 16:11:24
Documents
14
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atha-20230511.htm   iXBRL 8-K 62011
2 EX-99.1 atha-ex99_1.htm EX-99.1 168685
3 GRAPHIC img247042425_0.jpg GRAPHIC 9426
  Complete submission text file 0000950170-23-021239.txt   379639

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atha-20230511.xsd EX-101.SCH 2446
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atha-20230511_pre.xml EX-101.PRE 11413
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atha-20230511_lab.xml EX-101.LAB 13896
8 EXTRACTED XBRL INSTANCE DOCUMENT atha-20230511_htm.xml XML 4888
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

IRS No.: 453368487 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39503 | Film No.: 23911121
SIC: 2836 Biological Products, (No Diagnostic Substances)